GlassScriptPhysician profile
Jessalyn Elizabeth Meeks
NPI 1144425588
$2,016.12
in general payments reported to CMS, 2019-2025
24 companies · $215 in 2025
The $215 reported for 2025 was more than what 76% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $360 · 2020: $71.12 · 2021: $88.92 · 2022: $745 · 2023: $189 · 2024: $348 · 2025: $215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $752.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $751.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biomerieux INC | $666.67 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $112.81 | 2020-2024 | Vpriv |
| Corium, LLC | $112.04 | 2023-2025 | Azstarys |
| Sanofi Pasteur INC. | $111.37 | 2021-2025 | |
| Biofire Diagnostics, LLC | $99.37 | 2019 | |
| Pfizer INC. | $91.13 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $89.76 | 2024-2025 | |
| Cranial Technologies, INC | $79.64 | 2019-2024 | Doc Band |
| Neos Therapeutics, LP | $79.04 | 2019-2020 | |
| Shire North American Group INC | $72.76 | 2019 | |
| Kaleo, INC. | $69.36 | 2019-2024 | Auvi-Q |
| Ironshore Pharmaceuticals INC. | $67.79 | 2023-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $64.63 | 2021-2024 | Qelbree |
| Seqirus USA INC | $47.62 | 2023-2025 | Flucelvax, Flucelvax Quadrivalent |
| Astrazeneca Pharmaceuticals LP | $39.79 | 2023-2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $37.38 | 2019-2022 | |
| Glaxosmithkline, LLC. | $30.26 | 2020-2025 | Bexsero |
| Tris Pharma INC | $30.25 | 2019 | |
| Biomarin Pharmaceutical INC. | $28.39 | 2025 | Voxzogo 1.2mg |
| Verrica Pharmaceuticals INC. | $24.53 | 2023 | Ycanth |
| Phadia US INC. | $18.39 | 2024 | Immunocap |
| Genentech USA, INC. | $15.42 | 2019 | |
| Vertical Pharmaceuticals, LLC | $14.77 | 2025 | Relexxii |
| Teva Pharmaceuticals USA, INC. | $12.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessalyn Meeks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.